Eli Lilly lists 1.05M-share stake in Scribe Therapeutics

ELI LILLY & Co reported its initial beneficial ownership in Scribe Therapeutics, Inc. (SCTX) as a 10% owner.

Rhea-AI Filing Summary

ELI LILLY & Co reported its initial beneficial ownership in Scribe Therapeutics, Inc. (SCTX) as a 10% owner. It holds 1,054,828 shares of Common Stock on a direct basis. The company states that, after the closing of Scribe Therapeutics' initial public offering, it will cease to be a 10% owner and will no longer have Section 16 reporting obligations.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ELI LILLY & Co

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,054,828 shares (Direct)

Key Figures

Common Stock held: 1,054,828 shares Holding entries reported: 1 Buy transactions: 0 +1 more

4 metrics

Common Stock held 1,054,828 shares Directly owned Scribe Therapeutics Common Stock reported in the Form 3

Holding entries reported 1 Number of holding-line entries in the non-derivative table

Buy transactions 0 Number of reported purchase transactions in the transaction summary

Sell transactions 0 Number of reported sale transactions in the transaction summary

Key Terms

Section 16 reporting obligations, 10% Owner, initial public offering, beneficial ownership

4 terms

Section 16 reporting obligations regulatory

"will have no further Section 16 reporting obligations"

10% Owner regulatory

"will cease to be a 10% Owner"

initial public offering financial

"closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

beneficial ownership financial

"reported its initial beneficial ownership in Scribe Therapeutics"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Eli Lilly (LLY) report in this Form 3 regarding Scribe Therapeutics (SCTX)?

Eli Lilly reports its initial beneficial ownership position in Scribe Therapeutics as a 10% Owner, disclosing a direct holding of 1,054,828 shares of Common Stock as required under Section 16 for significant shareholders.

How many Scribe Therapeutics (SCTX) shares does Eli Lilly (LLY) hold?

Eli Lilly holds 1,054,828 shares of Scribe Therapeutics Common Stock. This position is reported as direct ownership in the Form 3 filing and represents its status as a 10% owner prior to the completion of Scribe’s initial public offering.

Will Eli Lilly (LLY) remain a 10% owner of Scribe Therapeutics (SCTX) after the IPO?

Eli Lilly states it will cease to be a 10% Owner after the closing of Scribe Therapeutics’ initial public offering. As a result, it indicates it will have no further Section 16 reporting obligations once that closing takes effect.

Does this Eli Lilly (LLY) Form 3 report any recent transactions in Scribe Therapeutics (SCTX) stock?

The Form 3 does not report any buy or sell transactions. It lists a holding entry showing 1,054,828 shares of Common Stock owned directly, serving as an initial statement of beneficial ownership rather than a record of trading activity.

What is the significance of Section 16 reporting for Eli Lilly’s stake in Scribe Therapeutics (SCTX)?

Section 16 requires 10% owners and insiders to report their holdings and certain trades. Eli Lilly notes that, after Scribe’s IPO closes and it ceases to be a 10% owner, it will have no further Section 16 reporting obligations related to this position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2026 - 09:45 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ELI LILLY & Co

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/23/2026

3. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,054,828	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

After giving effect to closing of the Issuer's initial public offering, the Reporting Person will cease to be a 10% Owner and, accordingly, will have no further Section 16 reporting obligations.

	/s/ Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)